MBX Biosciences (NASDAQ:MBX) Rating Lowered to “Sell” at Wall Street Zen

MBX Biosciences (NASDAQ:MBX) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Other research analysts have also recently issued reports about the stock. Citigroup restated an “outperform” rating on shares of MBX Biosciences in a report on Tuesday, May 12th. Mizuho increased their price objective on shares of MBX Biosciences from $57.00 to $91.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. Citizens Jmp lifted their target price on shares of MBX Biosciences from $76.00 to $86.00 and gave the stock a “market outperform” rating in a research report on Tuesday, May 12th. Stifel Nicolaus set a $56.00 target price on MBX Biosciences in a research note on Tuesday, May 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MBX Biosciences in a research report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $73.38.

MBX Biosciences Stock Performance

MBX Biosciences stock opened at $67.82 on Friday. The stock has a market capitalization of $3.23 billion, a price-to-earnings ratio of -28.14 and a beta of 0.10. MBX Biosciences has a 52-week low of $9.63 and a 52-week high of $72.64. The stock’s 50 day moving average price is $52.20 and its two-hundred day moving average price is $40.02.

MBX Biosciences (NASDAQ:MBX) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.10). On average, equities research analysts forecast that MBX Biosciences will post -2.88 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. CWM LLC raised its holdings in shares of MBX Biosciences by 28.9% during the 4th quarter. CWM LLC now owns 1,784 shares of the company’s stock valued at $56,000 after buying an additional 400 shares in the last quarter. Royal Bank of Canada grew its position in MBX Biosciences by 59.6% during the fourth quarter. Royal Bank of Canada now owns 1,532 shares of the company’s stock valued at $49,000 after acquiring an additional 572 shares during the last quarter. California State Teachers Retirement System raised its stake in shares of MBX Biosciences by 64.7% during the fourth quarter. California State Teachers Retirement System now owns 1,754 shares of the company’s stock worth $55,000 after acquiring an additional 689 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of MBX Biosciences in the 4th quarter valued at $28,000. Finally, Strs Ohio grew its holdings in shares of MBX Biosciences by 128.6% during the 1st quarter. Strs Ohio now owns 1,600 shares of the company’s stock valued at $48,000 after purchasing an additional 900 shares during the last quarter.

About MBX Biosciences

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.